OR WAIT null SECS
Aging populations and increased access to healthcare translates into opportunities for biopharmaceutical companies. JLL’s 2015 Life Sciences Outlook report highlights global clusters worth watching.
eBooks Volume 28, Issue 14
Distant destinations have never looked better for multinational and middle market life-sciences companies. While multinationals fill their innovation pipelines in North America, branded and generic-drug producers alike are finding fertile ground for growth in new markets in Asia and Latin America. Read this article and other articles in
The Future of Bioprocessing